Applying 3D constructs for gene therapy

  1. Myriam Sainz Ramos 123
  2. Caci, E 4
  3. Idoia Gallego 123
  4. Ilia Villate Beitia 123
  5. Sandra Ruiz Alonso 123
  6. Fátima García Villén 123
  7. Jon Zarate Sesma 123
  8. Gustavo Puras Ochoa 123
  9. José Luis Pedraz Muñoz 123
  10. Maldonado I 3
  1. 1 Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
  2. 2 Bioaraba, NanoBioCel Research Group.
  3. 3 NanoBiocel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country UPV/EHU
  4. 4 Medical Genetics Unit, IRCSS Institute Giannina Gaslini, Genova
Mostra les afiliacions +
Revista:
RESCIFAR Revista Española de Ciencias Farmacéuticas

ISSN: 2660-6356

Any de publicació: 2021

Títol de l'exemplar: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA

Volum: 2

Número: 2

Pàgines: 93-95

Tipus: Article

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Altres publicacions en: RESCIFAR Revista Española de Ciencias Farmacéuticas

Resum

The main objective of three-dimensional (3D) bioprinting technology is the development of 3D constructs combining biomaterials and cells to replicate tissues and organs. Using this technique, different kinds of epitheliums can be produced in order to imitate the in vivo environment with more precision than cell cultures. Such scaffolds are usually characterized prior to evaluate cellular response upon the addition of different drugs and genetic materials. The aim of this study was to make use of 3D bioprinting technology to develop scaffolds that mimic the in vivo lung environment to evaluate the capacity of niosomes (non-viral vectors) to deliver genetic material for the treatment of cystic fibrosis (CF) genetic disorder.

Fuente de los datos: Dialnet